Immunome Inc. — Director's Dealing 2021

May 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2021-05-25

Reporting Person: Sarma Purnanand D (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-25	Common Stock	P	10500	$18.41	Acquired	10500	Direct

Footnotes

F1: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $18.38 to $18.52, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.